Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.
Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wåhlander K, Gustafsson D, Badimon JJ. Sarich TC, et al. Among authors: fager gb. J Thromb Haemost. 2003 May;1(5):999-1004. doi: 10.1046/j.1538-7836.2003.00201.x. J Thromb Haemost. 2003. PMID: 12871368 Free article. Clinical Trial.
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D. Eriksson BI, et al. Thromb Haemost. 2002 Feb;87(2):231-7. Thromb Haemost. 2002. PMID: 11858482 Clinical Trial.
59 results